ArticleNature communications2023

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer.

Shen Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.